Development of a Therapeutic Education Program for Patients With Metastatic Prostate Cancer Treated With New Generation Hormone Therapy

Study Overview
=================
Brief Summary
-----------------
The development of a personalized therapeutic education program dedicated to patients with metastatic prostate cancer and receiving next-generation hormone therapy would improve their knowledge of the disease, medication adherence and quality of life.

Official Title
-----------------
Development of a Therapeutic Education Program for Patients With Metastatic Prostate Cancer Treated With New Generation Hormone Therapy: Construction and Feasibility Study

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Other: Focus group creation
* Other: Workshop


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with metastatic prostate cancer treated with enzalutamide or abiraterone acetate for at least 3 months The patient must have given their free and informed consent and signed the consent form The patient must be insured or the beneficiary of an insurance policy Exclusion Criteria: The subject is not in a fit state to express their consent It is impossible to give the subject informed information The patient is under safeguard of justice or state guardianship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Focus group<br> | Other: Focus group creation<br>* Patients will join with researchers for a 2 hour recorded group discussion to highlight themes identified to require educational intervention<br>|
| Workshop<br> | Other: Workshop<br>* Patients will attend 3-4 workshops on eg disease knowledge, medication management and side effects, adapted physical activity and nutrition<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Create a focus group | Transcribe interview and mark key points | Day 0 | 
| Patient satisfaction | Yes/no | End of workshops (max 2 months) | 
| Successful running of workshop | Yes/no evaluated by the workshop leader | End of workshops (max 2 months) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient participation rate in workshops |  | End of workshops (max 2 months) | 
| Patient-reported acceptability of programme | In-house questionnaire: 4 questions on 0-5 scale unacceptable to very acceptable and 4 open questions | End of workshops (max 2 months) | 
| Patient-reported satisfaction of programme | In-house questionnaire: 5 questions on 0-5 scale unsatisfied to very satisfied | End of workshops (max 2 months) | 
| Patient knowledge of their disease | In-house quiz: 7 multiple-choice questions | End of workshops (max 2 months) | 
| Patient quality of life | EQ-5D-3L | 1 month after last workshop | 
| Patient medication adherence | MMAS-9 questionnaire: good adherence is score = 8 | End of workshops (max 2 months) |